EasyM

09/04/2026

Early treatment failure after CAR-T: can we identify patients at risk?

A new study of patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel) found that:

• Prior BCMA-directed therapy, extramedullary disease, and CAR-HEMATOTOX ≥2 were independent predictors of early progression or death.
• MRD positivity at 3 months was associated with a significantly higher risk of early treatment failure.
• Less than complete response on FDG PET/CT at 3 months was also strongly associated with early treatment failure.

These findings highlight the potential value of early and sensitive disease monitoring after CAR-T, particularly for identifying patients who may need closer follow-up or new therapeutic strategies.

📄 Read the study: https://onlinelibrary.wiley.com/doi/10.1002/ajh.70425

09/01/2026

🩸 September is Blood Cancer Awareness Month 🩸

Did you know Multiple Myeloma is the 2nd most common blood cancer in the world?

This month and always, we pledge to:

- Stand with patients and families
- Raise awareness of Multiple Myeloma
- Drive research forward

Every share, every conversation, and every act of support brings us one step closer to a future with better options for all.

08/28/2026

Step Up for Canadians Living with Multiple Myeloma 🩸💪

On September 27, the EasyM team will join the Kitchener-Waterloo Multiple Myeloma March in support of
Myeloma Canada - National Page


Your donation helps:
- Advance research toward better treatments and outcomes
- Strengthen patient advocacy and access to new therapies

Double your impact ‼️

Donate by September 25 and your contribution could go twice as far.
At 2 PM ET on September 25, 2026, we will match the total amount raised by our team at that time, effectively doubling every donation made.

Every donation brings us closer to better treatments, better outcomes, and a future where multiple myeloma is no longer life-limiting.

Support our team and help us reach our goal:
https://support.myeloma.ca/site/TR/MultipleMyelomaMarch/General?pg=team&team_id=8535&fr_id=2014

Together, every step makes a difference.

08/14/2026

Today the FDA announced approval of Zenbexus (iberdomide), in combination with Darzalex (daratumumab) and dexamethasone, for patients whose multiple myeloma has returned after one or more previous treatments. Here's what patients should know: https://bit.ly/4qhcO5X

07/16/2026

📈 Sustained MRD negativity matters in newly diagnosed multiple myeloma.

In a cohort of 335 patients, sustained MRD-negative status was associated with significantly better PFS, while even one MRD-positive result predicted worse outcomes.

The study suggests that durable MRD negativity may outweigh the impact of high-risk cytogenetics and highlights the clinical value of serial MRD monitoring.

Read the abstract here: https://ascopubs.org/doi/pdf/10.1200/JCO.2026.44.16_suppl.7570

07/14/2026

Did you know? 💡

Blood-based monitoring is an emerging approach in multiple myeloma care.

EasyM is available in Canada and the United States.

If you have multiple myeloma and would like to learn more about blood-based monitoring, speak with your healthcare provider to discuss which monitoring options may be appropriate for your individual care.

Learn more on our website: www.easym.com

07/07/2026

Check out the latest HealthTree for Multiple Myeloma interview with our Senior Scientist where they discuss our newest research on EasyM, our blood-based MRD test for multiple myeloma 📣

Watch the interview to learn more 🎥 : https://www.youtube.com/watch?v=4HiTbsasHns&t=13s

EasyM is currently available for patients in the US and Canada.

Can a simple blood test replace bone marrow biopsies for MRD testin...

07/03/2026

🩸 Can a blood test help monitor myeloma after CAR T therapy?

New research suggests EasyM, a highly sensitive blood test, detects tiny amounts of myeloma protein after CAR T treatment without repeated bone marrow biopsies.

Find the poster and abstract here: https://www.easym.com/evaluating-m-protein-kinetics-post-car-t-therapy-with-easym-and-comparison-with-bone-marrow-based-mrd/ #

07/02/2026

New research alert 📣 📰

Poster from Monash University presented at EHA 2026 compared the EasyM and EXENT blood tests for monitoring multiple myeloma.

The study found that EasyM detected lower levels of M-protein, particularly in patients with deep treatment responses, while showing strong overall correlation with EXENT.

Find the poster and abstract here: https://www.easym.com/easym-versus-exent-for-mrd-in-mm/

06/24/2026

Reflecting on EHA 2026 💭

We're grateful for the opportunity to present two posters and connect with so many researchers, clinicians, and collaborators.

One of the highlights was discussing the growing role and importance of blood-based MRD monitoring in multiple myeloma. The thoughtful conversations, questions, and shared perspectives reinforced the excitement around advancing less invasive, more accessible approaches to disease monitoring.

Thank you to everyone who stopped by, shared insights, and engaged with us throughout the meeting. We're excited to continue the conversation and help advance the future of blood-based MRD in MM.